Literature DB >> 2453093

Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. II. Endocrinological analysis.

K Okada1, K Oishi, O Yoshida, K Sudo, M Kawase, R Nakayama.   

Abstract

The results of hormonal investigation of effects of an antiandrogen, Oxendolone (OXD), alone or in combination with medroxyprogesterone acetate (MPA), on experimentally induced canine BPH are reported. Seventeen beagle dogs were divided into 5 groups: 2 castrate controls for Group 0, 3 BPH controls for Group 1 which received 3 alpha-androstanediol (3 alpha-A) and estradiol (E2) for one year, and 12 dogs consisting of 3 groups which received 3 alpha-A and E2 for 6 months followed by testosterone propionate (TP) and E2 for another 6 months. The last 3 groups were treated with either 200 mg/week of OXD (Group 3) or OXD + 30 mg/week of MPA (Group 4), and otherwise untreated with these hormones (Group 2, T-E controls). On the blood hormone analysis, both T and 5 alpha-dihydrotestosterone (DHT) were generally lowered in the T-E administered groups (Group 2, 3 and 4) compared to those in Group 1. While MPA significantly decreased these androgen levels, OXD did not influence at all. The concentrations of E2 were similar. Although T content in the prostate did not differ significantly within the experimental groups, DHT was the highest in Group 1 and the lowest in Group 4 and was nearly the same level to Group 0. MPA reduced tissue DHT content but OXD did not. In the receptor assay study, nuclear androgen receptor (AR) content in Group 3 and 4 was significantly lower than that in Group 1. No obvious decrease in nuclear AR content could be seen among the other groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453093     DOI: 10.1007/BF00261959

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  21 in total

1.  The Etiology of Benign Prostatic Hypertrophy.

Authors:  C Huggins
Journal:  Bull N Y Acad Med       Date:  1947-12

2.  Studies on the canine prostate gland. I. Factors influencing its size and weight.

Authors:  J D O'SHEA
Journal:  J Comp Pathol       Date:  1962-07       Impact factor: 1.311

3.  Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol.

Authors:  R J Moore; J M Gazak; J D Wilson
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

4.  An improved assay for nuclear estrogen receptor in experimental and human breast cancer.

Authors:  R E Garola; W L McGuire
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

5.  Androgen metabolism in the hypertrophic prostate.

Authors:  J D Wilson; R E Gloyna; P K Siiteri
Journal:  J Steroid Biochem       Date:  1975 Mar-Apr       Impact factor: 4.292

6.  Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.

Authors:  R Nakayama; M Masuoka; T Masaki; K Shimamoto
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1979

7.  5alpha-reduction of an anti-androgen TSAA-291, 16beta-ethyl-17beta-hydroxy-4-estren-3-one, by nuclear 5alpha-reductase in rat prostates.

Authors:  K Sudo; K Yoshida; Y Akinaga; R Nakayama
Journal:  Steroids       Date:  1981-07       Impact factor: 2.668

8.  Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.

Authors:  J Trachtenberg; L L Hicks; P C Walsh
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

9.  Demonstration of a cytoplasmic receptor protein for oestrogen in the canine prostate gland.

Authors:  N Chaisiri; Y Valotaire; B A Evans; C G Pierrepoint
Journal:  J Endocrinol       Date:  1978-07       Impact factor: 4.286

10.  Specific interaction of radioactive anti-androgen TSAA-291 with androgen receptor in rat prostates.

Authors:  K Sudo; K Yoshida; R Nakayama
Journal:  Acta Endocrinol (Copenh)       Date:  1982-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.